INmune Bio, Inc.
NASDAQ: INMB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David J. Moss
- Employees
- 13
- Headquarters
- Boca Raton, United States
- IPO year
- 2019
- Market cap
- $35.9M
- Website
- https://www.inmunebio.com
Loading INMB…
Loading profile data…Frequently asked questions about INMB
What does INmune Bio, Inc. (INMB) do?
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as b...
Where does INMB trade?
INmune Bio, Inc. (INMB) trades on the NASDAQ Capital Market.
What sector is INMB in?
INmune Bio, Inc. (INMB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of INmune Bio, Inc.?
David J. Moss is the chief executive officer of INmune Bio, Inc. (INMB).
Where is INmune Bio, Inc. headquartered?
INmune Bio, Inc. is headquartered in United States.
Does INMB pay a dividend?
INmune Bio, Inc. (INMB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did INMB go public?
INmune Bio, Inc. (INMB) completed its initial public offering in 2019.